Advertisement
INCY vs VRTX
VRTX vs INCY Stock Comparison: Earnings Recap Q4 2025 Results
Key Takeaways
- Vertex (VRTX) reported Q4 2025 revenue of $3.19 billion, up 10% YoY, beating estimates slightly, but non-GAAP EPS of $5.03 missed consensus of ~$5.07-$5.15.
- Incyte (INCY) delivered Q4 revenue of $1.51 billion, up 28% YoY and beating estimates by 12%, though non-GAAP EPS of $1.80 missed expectations of $1.94.
- VRTX full-year 2025 revenue hit $12.0 billion (9% growth); INCY reached $5.14 billion (21% growth), highlighting INCY's faster top-line expansion.
- Both stocks dipped post-earnings: VRTX down ~1% after-hours on EPS miss; INCY fell ~8% on EPS miss and conservative 2026 guidance.+Stock+Falls+on+Q4+2025+Earnings)
- VRTX guides 2026 revenue to $12.95B-$13.1B with $500M+ from non-CF; INCY eyes $4.77B-$4.94B, driven by Jakafi and Opzelura growth.
- Diversification key: VRTX advances CASGEVY and pain therapies; INCY bolsters oncology and inflammation pipeline.
Earnings Context and Why This Comparison Matters
Vertex Pharmaceuticals (VRTX), a leader in cystic fibrosis treatments, and Incyte Corporation (INCY), focused on oncology and immunology, represent contrasting biotech strategies. VRTX's Q4 2025 earnings recap underscores its stable CF franchise growth amid diversification into gene therapies like CASGEVY and acute pain drug JOURNAVX. INCY's results highlight robust demand for Jakafi and Opzelura, fueling pipeline investments in hematology and autoimmune diseases. Comparing them aids investors assessing earnings quality, growth trajectories, and risk in biotech, where VRTX offers scale and INCY higher growth potential amid competitive oncology dynamics.
VRTX Earnings Focus
Vertex reported Q4 2025 total revenue of $3.19 billion, up 10% year-over-year, surpassing estimates of $3.16B-$3.18B, driven by its CF franchise and early contributions from CASGEVY ($54M) and JOURNAVX launch. Full-year revenue reached $12.0 billion, a 9% increase. Non-GAAP net income was $1.3 billion, with diluted EPS of $5.03, missing consensus estimates of $5.07-$5.15 due to higher R&D and SG&A expenses ($1.36B non-GAAP). GAAP EPS was $4.65. The stock dipped ~1% after-hours, reflecting the EPS shortfall despite revenue beat and solid 2026 guidance of $12.95B-$13.1B total revenue, including $500M+ from non-CF products. Key themes: CF expansion via ALYFTREK approvals, CASGEVY infusions ramping, and pipeline milestones like povetacicept BLA in H1 2026.
INCY Context and Earnings Relevance
Incyte's Q4 2025 earnings, released February 10, showed total revenue of $1.51 billion, up 28% YoY and beating estimates by 12% ($1.35B consensus), propelled by Jakafi ($828M, +7% YoY), Opzelura ($207M, +28%), and oncology launches like Niktimvo ($56M). Full-year revenue hit $5.14 billion (+21%). Non-GAAP diluted EPS was $1.80, missing $1.94 consensus amid elevated expenses, versus $1.43 YoY. GAAP net income $299M; non-GAAP $368M. Shares plunged ~8% on the EPS miss and 2026 guidance of $4.77B-$4.94B net product revenue (below some expectations), with Jakafi $3.22B-$3.27B, Opzelura $750M-$790M. Business momentum persists via pipeline: 14 pivotal trials, povorcitinib NDA Q1 2026, and oncology advancements.
Head-to-Head Earnings and Market Comparison
VRTX's earnings reflect mature scale with $3.19B quarterly revenue versus INCY's $1.51B, but INCY posted superior 28% YoY growth versus VRTX's 10%, signaling stronger near-term momentum in oncology/immunology. VRTX's non-GAAP margins benefit from CF dominance (~90% revenue), while INCY diversifies across Jakafi (64% of FY revenue) and newer products. Growth drivers: VRTX's non-CF ramp (CASGEVY, JOURNAVX, povetacicept); INCY's Opzelura expansion and 14 late-stage trials. Risks differ—VRTX faces CF patent cliffs longer-term; INCY contends with Jakafi competition and biosimilar pressures. Market sentiment post-earnings leaned negative for both (VRTX -1%, INCY -8%), but VRTX's $12.3B cash hoard dwarfs INCY's $3.6B, supporting R&D. Valuation-wise, VRTX trades at premium multiples on stability; INCY offers value on growth.
Tickeron AI Verdict
Tickeron's AI models currently favor VRTX based on superior earnings stability, larger scale, and diversified pipeline momentum beyond CF, including promising non-CF revenue growth projected at $500M+ in 2026. INCY's faster revenue expansion and oncology exposure present upside, but higher execution risks and recent guidance concerns temper enthusiasm. Probabilistic edge to VRTX for consistent quality amid biotech volatility; not investment advice.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and VRTX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 0 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 6 TA indicator(s) are bullish while VRTX’s TA Score has 4 bullish TA indicator(s).
- INCY’s TA Score: 6 bullish, 2 bearish.
- VRTX’s TA Score: 4 bullish, 4 bearish.
Price Growth
INCY (@Biotechnology) experienced а -0.14% price change this week, while VRTX (@Biotechnology) price change was +5.98% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.40%. For the same industry, the average monthly price growth was -1.21%, and the average quarterly price growth was +9.78%.
Reported Earning Dates
INCY is expected to report earnings on Aug 04, 2026.
VRTX is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (-1.40% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| INCY | VRTX | INCY / VRTX | |
| Capitalization | 19.5B | 114B | 17% |
| EBITDA | 1.87B | 4.98B | 38% |
| Gain YTD | -1.149 | -0.651 | 177% |
| P/E Ratio | 13.79 | 26.73 | 52% |
| Revenue | 5.36B | 12.2B | 44% |
| Total Cash | 4.02B | 7.25B | 55% |
| Total Debt | 39.4M | 1.99B | 2% |
INCY | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 74 | 34 | |
SMR RATING 1..100 | 32 | 40 | |
PRICE GROWTH RATING 1..100 | 48 | 53 | |
P/E GROWTH RATING 1..100 | 100 | 49 | |
SEASONALITY SCORE 1..100 | 50 | 46 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCY's Valuation (68) in the Biotechnology industry is in the same range as VRTX (79). This means that INCY’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's Profit vs Risk Rating (34) in the Biotechnology industry is somewhat better than the same rating for INCY (74). This means that VRTX’s stock grew somewhat faster than INCY’s over the last 12 months.
INCY's SMR Rating (32) in the Biotechnology industry is in the same range as VRTX (40). This means that INCY’s stock grew similarly to VRTX’s over the last 12 months.
INCY's Price Growth Rating (48) in the Biotechnology industry is in the same range as VRTX (53). This means that INCY’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's P/E Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for INCY (100). This means that VRTX’s stock grew somewhat faster than INCY’s over the last 12 months.
| INCY | VRTX | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 57% | 2 days ago 66% |
| MACD ODDS (%) | N/A | 2 days ago 64% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 62% | 2 days ago 68% |
| Advances ODDS (%) | 5 days ago 62% | 3 days ago 62% |
| Declines ODDS (%) | 2 days ago 59% | 19 days ago 44% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 58% |
| Aroon ODDS (%) | 2 days ago 63% | 2 days ago 28% |
Advertisement
INCY and
Correlation & Price change
A.I.dvisor indicates that over the last year, INCY has been loosely correlated with BMRN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then BMRN could also see price increases.
| Ticker / NAME | Correlation To INCY | 1D Price Change % | ||
|---|---|---|---|---|
| INCY | 100% | -1.20% | ||
| BMRN - INCY | 43% Loosely correlated | -0.56% | ||
| PTCT - INCY | 41% Loosely correlated | -1.01% | ||
| TECH - INCY | 39% Loosely correlated | -0.33% | ||
| AXON - INCY | 39% Loosely correlated | +3.02% | ||
| REGN - INCY | 37% Loosely correlated | -0.97% | ||
More | ||||